Skopos Labs, Inc. Savara Inc Transaction History
Skopos Labs, Inc.
- $453 Million
- Q1 2025
A detailed history of Skopos Labs, Inc. transactions in Savara Inc stock. As of the latest transaction made, Skopos Labs, Inc. holds 23,611 shares of SVRA stock, worth $70,124. This represents 0.01% of its overall portfolio holdings.
Number of Shares
23,611Holding current value
$70,124% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding SVRA
# of Institutions
143Shares Held
162MCall Options Held
54.8KPut Options Held
4.1K-
Nea Management Company, LLC Timonium, MD24.5MShares$72.7 Million6.43% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA17.6MShares$52.3 Million16.36% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA12.4MShares$36.7 Million8.25% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA11.5MShares$34 Million2.0% of portfolio
-
Vestal Point Capital, LP New York, NY11MShares$32.7 Million2.18% of portfolio
About Savara Inc
- Ticker SVRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 114,043,000
- Market Cap $339M
- Description
- Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.